loading
Taysha Gene Therapies Inc stock is traded at $5.13, with a volume of 2.64M. It is up +5.29% in the last 24 hours and up +67.37% over the past month. Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.88
Open:
$4.88
24h Volume:
2.64M
Relative Volume:
0.47
Market Cap:
$1.40B
Revenue:
$8.10M
Net Income/Loss:
$-92.72M
P/E Ratio:
-15.09
EPS:
-0.34
Net Cash Flow:
$-82.52M
1W Performance:
+16.25%
1M Performance:
+67.37%
6M Performance:
+312.71%
1Y Performance:
+155.63%
1-Day Range:
Value
$4.86
$5.15
1-Week Range:
Value
$4.3201
$5.21
52-Week Range:
Value
$1.05
$5.40

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Name
Taysha Gene Therapies Inc
Name
Phone
(214) 612-0000
Name
Address
3000 PEGASUS PARK DRIVE, DALLAS
Name
Employee
73
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TSHA's Discussions on Twitter

Compare TSHA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
5.13 1.33B 8.10M -92.72M -82.52M -0.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.56 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.33 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.46 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
800.99 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
330.86 35.16B 4.56B -176.77M 225.30M -1.7177

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-11-25 Initiated BofA Securities Buy
Jun-27-24 Initiated BMO Capital Markets Outperform
Apr-09-24 Initiated Piper Sandler Overweight
Feb-01-23 Downgrade Jefferies Buy → Hold
Jan-27-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-22 Downgrade Goldman Buy → Neutral
Mar-09-22 Initiated Robert W. Baird Outperform
Mar-01-22 Initiated Wells Fargo Overweight
Feb-18-22 Initiated SMBC Nikko Outperform
Dec-16-21 Initiated Guggenheim Buy
Jul-16-21 Initiated Needham Buy
Jun-24-21 Initiated Truist Buy
Jun-15-21 Initiated BTIG Research Buy
Jun-09-21 Initiated Wedbush Outperform
Jun-08-21 Initiated JMP Securities Mkt Outperform
May-19-21 Initiated Cantor Fitzgerald Overweight
May-11-21 Resumed Jefferies Buy
Feb-24-21 Initiated William Blair Outperform
Jan-05-21 Initiated Oppenheimer Outperform
Oct-19-20 Initiated Chardan Capital Markets Buy
Oct-19-20 Initiated Goldman Buy
Oct-19-20 Initiated Jefferies Buy
Oct-19-20 Initiated Morgan Stanley Overweight
View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

pulisher
11:28 AM

Earnings visualization tools for Taysha Gene Therapies Inc.Weekly Trading Summary & Fast Entry Momentum Trade Alerts - newser.com

11:28 AM
pulisher
10:08 AM

Why Taysha Gene Therapies Inc. is moving today2025 Price Action Summary & Weekly High Return Forecasts - newser.com

10:08 AM
pulisher
Oct 10, 2025

Has Taysha Gene Therapies Inc. formed a bullish divergenceJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory - MSN

Oct 10, 2025
pulisher
Oct 10, 2025

Tick level data insight on Taysha Gene Therapies Inc. volatilityJuly 2025 Sentiment & Free Reliable Trade Execution Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

What MACD and RSI say about Taysha Gene Therapies Inc.2025 Volume Leaders & Smart Allocation Stock Tips - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Can Taysha Gene Therapies Inc. stock hit record highs again2025 Volatility Report & Verified Entry Point Signals - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Taysha Gene Therapies Inc. trending in predictive chart modelsPortfolio Return Report & Consistent Income Trade Ideas - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Weiss Ratings Reiterates Sell (D-) Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Taysha Gene Therapies Hits Day High with 7.2% Surge in Stock Price - Markets Mojo

Oct 09, 2025
pulisher
Oct 09, 2025

Taysha Gene Therapies (TSHA) Reveals Enhanced Trial Results for Rett Syndrome - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - The Manila Times

Oct 09, 2025
pulisher
Oct 09, 2025

Taysha Gene Therapies Presents New Supplemental Data - GlobeNewswire

Oct 09, 2025
pulisher
Oct 09, 2025

Will Taysha Gene Therapies Inc. stock continue dividend increasesMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Analyzing net buyer seller activity in Taysha Gene Therapies Inc.Weekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Visual analytics tools that track Taysha Gene Therapies Inc. performanceEarnings Beat & Daily Technical Stock Forecast Reports - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

Taysha Gene Therapies Hits Day Low of $4.40 Amid Price Pressure - Markets Mojo

Oct 07, 2025
pulisher
Oct 07, 2025

Taysha Gene Therapies, Inc. Sees Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo

Oct 07, 2025
pulisher
Oct 07, 2025

Taysha soars on FDA breakthrough therapy status for lead asset - MSN

Oct 07, 2025
pulisher
Oct 06, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9%Time to Sell? - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Taysha Gene Therapies Hits New 52-Week High at $5.40 - Markets Mojo

Oct 06, 2025
pulisher
Oct 06, 2025

Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential (TSHA) - Seeking Alpha

Oct 06, 2025
pulisher
Oct 06, 2025

Will Taysha Gene Therapies Inc. stock maintain growth story2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

How to interpret RSI for Taysha Gene Therapies Inc. stockWeekly Trade Analysis & Low Volatility Stock Recommendations - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Taysha Snags FDA Breakthrough Therapy Designation for Rett Syndrome Gene Therapy TSHA-102 - CGTLive®

Oct 05, 2025
pulisher
Oct 04, 2025

How Recent Developments Are Rewriting the Story for Taysha Gene Therapies - Yahoo Finance

Oct 04, 2025
pulisher
Oct 04, 2025

Taysha Gene Therapies (TSHA) Gets a Buy from Canaccord Genuity - The Globe and Mail

Oct 04, 2025
pulisher
Oct 04, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 04, 2025
pulisher
Oct 04, 2025

Needham & Company LLC Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World

Oct 04, 2025
pulisher
Oct 04, 2025

Best Small Cap Stocks To Add to Your Watchlist – October 2nd - Defense World

Oct 04, 2025
pulisher
Oct 03, 2025

Taysha Gene Therapies stock hits 52-week high at 5.05 USD - Investing.com Nigeria

Oct 03, 2025
pulisher
Oct 03, 2025

1.29M-option grant: Taysha grants 1,289,600 stock options at $3.18, 4-yr vesting under Nasdaq rule - Stock Titan

Oct 03, 2025
pulisher
Oct 03, 2025

US FDA Backing Is A Breakthrough For Taysha’s Gene Therapy - insights.citeline.com

Oct 03, 2025
pulisher
Oct 03, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛

Oct 03, 2025
pulisher
Oct 03, 2025

A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $8 to $14 - 富途牛牛

Oct 03, 2025
pulisher
Oct 03, 2025

Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy | FinancialCont - FinancialContent

Oct 03, 2025
pulisher
Oct 03, 2025

Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals - Stocktwits

Oct 03, 2025
pulisher
Oct 03, 2025

Could Taysha's FDA Alignment Fast-Track Its BLA Submission? - RTTNews

Oct 03, 2025
pulisher
Oct 03, 2025

Robert W. Baird Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World

Oct 03, 2025
pulisher
Oct 03, 2025

Analyzing drawdowns of Taysha Gene Therapies Inc. with statistical toolsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Taysha Gene Therapies Target of Unusually High Options Trading (NASDAQ:TSHA) - Defense World

Oct 03, 2025

Taysha Gene Therapies Inc Stock (TSHA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Taysha Gene Therapies Inc Stock (TSHA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Nagendran Sukumar
President and Head of R&D
Sep 10 '25
Option Exercise
0.70
41,150
28,760
1,206,439
Nagendran Sukumar
President and Head of R&D
Sep 10 '25
Sale
3.23
200,000
646,000
1,006,439
$85.13
price up icon 1.59%
$22.83
price up icon 7.21%
$32.80
price up icon 3.03%
$102.59
price up icon 0.56%
$165.04
price up icon 1.60%
biotechnology ONC
$330.86
price up icon 3.39%
Cap:     |  Volume (24h):